Breathing pattern during bronchial challenge in humans


ABSTRACT: Increases in minute ventilation (VE) have been observed during exacerbations of asthma and in response to administration of histamine. However, it is not yet clear how the breathing pattern is affected, and whether the increase in VE is found in general.

In the present study, the effects of inhalation of histamine on respiratory frequency (fR), tidal volume (VT), V'E, and on functional residual capacity (FRC) were evaluated in 63 humans. Forty-four subjects were hyperresponsive (BHR+). In each of these subjects, the doses of histamine applied for the present study were evaluated in 63 humans. Forty-four subjects were hyperresponsive (BHR+).

Of the 19 nonhyperresponsive subjects (BHR-), the increase in V'E was found in general.

In the present study, the effects of inhalation of histamine on respiratory frequency (fR), tidal volume (VT), V'E, and on functional residual capacity (FRC) were evaluated in 63 humans. Forty-four subjects were hyperresponsive (BHR+). In each of these subjects, the doses of histamine applied for the present study (mean 3.5 mg·mL⁻¹) caused a decrease in forced expiratory volume in one second (FEV₁) that was greater than 20% of the control value. The dose of histamine applied in the 19 nonhyperresponsive subjects (BHR-) was substantially larger (8.0 mg·mL⁻¹) whilst for this dose the decrease in FEV₁ was less than 20% of control value.

After histamine, fR was significantly increased in both subgroups of subjects, BHR+ and BHR-. The increase in V'E was significant in BHR- but not significant in BHR+.

In general, the changes in V'E, fR and VT were not uniform; comparable numbers of subjects responded with increases (n=33) and decreases (n=30) in V'E. For fR 40 subjects responded with an increase and 23 with a decrease, and for VT these numbers were 26 and 37, respectively. The increase in FRC after histamine was significantly larger in BHR+ subjects than in BHR-.

These findings may be interpreted to indicate that different mechanisms with opposite effects may be operating simultaneously, e.g. excitation of central inspiratory activity by stimulation of rapidly-adapting pulmonary stretch receptors, which will promote increases in respiratory frequency, tidal volume and minute ventilation, and bronchoconstriction with increased airway resistance, which will promote decreases in these parameters. As a consequence, depending on the net result of these opposite contributions to, e.g. minute ventilation, administration of histamine will cause an increase in minute ventilation in one subject and a decrease in another.


Bronchoconstriction and hyperventilation occur during exacerbations of asthma. Generally, arterial carbon dioxide tension (Paco₂) does not change, or even decreases during exacerbations of asthma, indicating that ventilation must have increased [1, 2]. It has been known for years that patients with asthma hyperventilate when acutely ill [3-5]. It has also been found that minute ventilation (VE) increases in response to progressive methacholine-induced and histamine-induced bronchoconstriction [5-9]. Other studies, however, have indicated that inhaled histamine or methacholine may result in a rapid, sometimes shallow, breathing pattern [10], or that the breathing pattern is not changed in response to histamine or methacholine [11, 12]. Thus, results on ventilatory responses to induced bronchoconstriction reported in the literature are not consistent.

STROMBERG and GUSTAFSSON [13] found that, during a histamine challenge, 4 out of 8 patients responded with an increase in VE, whereas V'E was unchanged or tended to decrease in the remaining patients. These authors suggested that the latter patients were "ventilatory nonresponders".

Recently, it has been shown, in a selected group of patients with asthma, that during histamine challenge tests changes in breathing pattern occur prior to changes in the forced expiratory volume in one second (FEV₁) [14]. This finding suggests that the increase in airway resistance does not play the only role in the change in pattern of breathing, and, furthermore, that vagal airway receptors may be involved by direct stimulation. It is well-known that pulmonary receptors influence the breathing pattern [15, 16]. The duration of inspiration (ti) is controlled mainly by slowly-adapting stretch receptors (SARs) through the off-switch mechanism, and, at least in part, duration of expiration (te) is determined by rapidly-adapting stretch receptors (RARs) [17-19]. In a previous study in cats, we found that respiratory frequency (fR) increased significantly (p<0.01) in response to stimulation of RARs by intravenous administration of histamine [20]. During mechanical stimulation of RARs by continuous negative airway pressure, an increase in fR was also found [21]. RARs can be stimulated by histamine in two ways: mechanically (by bronchoconstriction) and chemically [22-25].

Functional residual capacity (FRC) may increase after
administration of histamine. This is due to the concomitant bronchoconstriction and/or an increase in end-tidal inspiratory activity (ETIA) [26]. Changes in RCR may indirectly influence the breathing pattern because of the relationship between lung volume and the activity of pulmonary stretch receptors. Furthermore, an increase in RCR may limit the increase in VT.

It is not yet clear how the breathing pattern changes during exacerbations of asthma and induced bronchoconstriction. The aims of the present study, therefore, were: 1) to evaluate the effects of administration of histamine on the breathing pattern and on RCR in humans; and 2) to evaluate whether the degree of bronchial responsiveness plays a role in histamine-induced changes in VT.

**Methods**

**Subjects**

Sixty three subjects participated in this study. Characteristics of the subjects are presented in table 1. Bronchodilators were withheld for at least 8 h prior to the study. In a standardized histamine challenge test, the provocative concentration of histamine which caused a fall of ≥20% in FEV1 (PC20) [27, 28] was determined. To shorten the duration of the test, the starting concentration of histamine varied depending on the response to an aerosol of saline, and medication requirements [28–30]. A histamine concentration of 8 mg·mL⁻¹ was used as the upper limit of the test. Forty four subjects showed bronchial hyperresponsiveness (PC20 ≤8 mg·mL⁻¹) (“BHR+”). The remaining 19 subjects were not hyperresponsive (“BHR-”). Informed consent was obtained from all subjects. The subjects were naive with respect to the scientific goals of the study. The study was approved by the hospital Medical Ethics Committee.

**Experimental set-up**

Aerosols were generated by a DeVilbiss 646 jet nebulizer ( DeVilbiss Co., Somerset, PA, USA). The calibrated output of the nebulizer was 0.13 mL·min⁻¹. The histamine concentration that was used in the further experiments depended on the individual result of the histamine challenge protocol. In BHR+ subjects, ventilatory parameters were studied at the PC20 dose. In BHR- subjects, the ventilatory parameters were studied at a histamine dose of 8 mg·mL⁻¹.

FEV1 and FVC were measured by a pneumotachograph (Fukuda Sangyo, Tokyo, Japan). Changes (Δ) in FRC, fR tidal volume (Vr) and V'E were calculated from the spiromgrams recorded before and after inhalation of histamine. Two methods were applied to record these spiromgrams: 1) using a wedge spirometer in a closed breathing circuit; and 2) using respiratory inductive plethysmography (RIP) (Respirac®; Respirac CA, Ardsley, USA). Values were related to the reference values of the European Respiratory Society [31].

Forty one subjects (29 BHR+ and 12 BHR-) were connected to the closed breathing circuit by a mouthpiece. A blower maintained a constant bias flow in the circuit (120 L·min⁻¹). Gas was sampled continuously from the circuit for measurement of the oxygen concentration (Taylor Servomex, Sussex, UK), and subsequently fed back into the system (fig. 1). Oxygen was supplied to maintain a constant oxygen concentration (21%) in the circuit. Exhaled CO2 was absorbed by soda lime. A mismatch between O2 supply and O2 uptake by the subject would cause the baseline of the spirometer signal to drift one way or the other, which would affect the result for ΔFRC. The shift of the baseline of the spirometer signal (ΔV) is proportional to the deviation of the O2 concentration (ΔCO2) from 21%. The relationship between ΔV and ΔCO2 was determined experimentally by adding a known amount of pure oxygen to the system and reading the corresponding change in CO2. With the help of this relationship, we have corrected the raw data for ΔFRC for the aforementioned CO2-related shift of the baseline of the spirometer signal. The inaccuracy of the correction was ±6 mL. This error adds to the overall random error in the determination of ΔFRC. The DeVilbiss 646 jet nebulizer was connected to the circuit near the mouthpiece (fig. 1).

The remaining subjects (15 BHR+ and 7 BHR-) were connected to the RIP system and via a mouthpiece to the nebulizer. The RIP was used in the direct current (DC)-mode. Volume calibration of the Respirac was performed with a spirometer (Hospal, Littleton, CO, USA). The RIP was used as the upper limit of the test. Forty four subjects showed bronchial hyperresponsiveness (PC20 ≤8 mg·mL⁻¹). The remaining 19 subjects were not hyperresponsive (“BHR-”). Informed consent was obtained from all subjects. The subjects were naive with respect to the scientific goals of the study. The study was approved by the hospital Medical Ethics Committee.

**Table 1. - Characteristics of subjects**

<table>
<thead>
<tr>
<th>Subjects n</th>
<th>Total</th>
<th>BHR+</th>
<th>BHR-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex M/F</td>
<td>63</td>
<td>44</td>
<td>19</td>
</tr>
<tr>
<td>Age yrs</td>
<td>34±2</td>
<td>35±2</td>
<td>34±2</td>
</tr>
<tr>
<td>Height cm</td>
<td>173±1</td>
<td>172±1</td>
<td>175±2</td>
</tr>
<tr>
<td>Histamine mg·mL⁻¹</td>
<td>4.8±0.44</td>
<td>3.5±0.50</td>
<td>8.0±0.00***</td>
</tr>
<tr>
<td>FEV1 % pred control histamine</td>
<td>92±2</td>
<td>87±2</td>
<td>103±3***</td>
</tr>
<tr>
<td>70±3##</td>
<td>60±2##</td>
<td>93±3###</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as absolute number or as mean±SEM. % pred: percentage of predicted value; M: male; F: female; FEV1: forced expiratory volume in one second; BHR+: hyperresponsive; BHR-: nonhyperresponsive. Note that the concentration of histamine administered to the subgroup of subjects with BHR- was about twice that administered to the subgroup of subjects with BHR+. ##: p<0.001, compared to control values; ###: p<0.001, compared to BHR+ values.
USA), just prior to the administration of the aerosol of histamine, and immediately after the recording had been ended while the subject was still sitting in the same position. If the two calibration factors differed by more than 10%, the measurement was excluded from the study. Thus, for each subject, a conversion factor was calculated from the lung volume changes measured with the spirometer and the associated deflections obtained from the RIP.

The spirometers were recorded with a multichannel X-t recorder (Kip, The Netherlands) for off-line analysis of the changes in $VE$, $VT$, $fR$ and $FRC$. All subjects were tested in the sitting position, whilst breathing through the mouthpiece with the nose clipped. When the subjects were seated in a relaxed posture, they were asked to remain seated in that way until the end of the recording. Thus, with the co-operation of the subjects, we were able to minimize the impact of postural muscles on the volume changes recorded. To divert their attention from breathing, the subjects were asked to concentrate on a poster placed in front of them.

**Experimental protocol**

Recording was started after the subjects had been connected to the mouthpiece. The uninterrupted recording included control breaths, breaths during the period of 2 min of inhalation of histamine, and for at least 1 min following inhalation of histamine. FEV1 and FVC were measured immediately before this recording, and 1.5 min after inhalation of histamine had been stopped.

**Statistical analysis**

From each recording, two sets of values for $fR$, $VT$, and $VE$ were calculated from five consecutive control breaths just prior to the inhalation of histamine, and from five consecutive breaths 1 min after inhalation of histamine, respectively. The $\Delta FRC$ was calculated from the shift in the baseline of the spirometer signal between these two groups of breaths.

Differences between the results before (control) and after inhalation of histamine, and differences between the results of the two groups (BHR+ and BHR-) were evaluated for statistical significance using the t-test for paired observations and the $t$-test for unpaired observations, respectively. A $p$-value of less than 0.05 was considered to be significant.

**Results**

The characteristics of the subjects are presented in table 1. Sex, age and height were not significantly different between BHR+ and BHR-. For BHR+, BHR- and the group as a whole, FEV1 decreased significantly in response to the dose of histamine applied as compared with control values. The mean concentration of histamine administered to BHR+ (3.5 mg·mL⁻¹) was less than half of that administered to BHR- (8.0 mg·mL⁻¹). Nonetheless, the decrease in FEV1 in BHR+ was considerably larger than that in BHR-.

**Table 2.** - Effects of aerosolized histamine on breathing pattern

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Total</th>
<th>BHR+</th>
<th>BHR-</th>
</tr>
</thead>
<tbody>
<tr>
<td>$VE$ L·min⁻¹</td>
<td>control</td>
<td>8.1±0.4</td>
<td>8.3±0.4</td>
</tr>
<tr>
<td>$fR$ breaths·min⁻¹</td>
<td>control</td>
<td>16.3±0.7</td>
<td>17.1±0.8</td>
</tr>
<tr>
<td>$VE$ mL</td>
<td>control</td>
<td>524±21</td>
<td>496±19</td>
</tr>
<tr>
<td>$FRC$ % pred</td>
<td>histamine</td>
<td>514±21</td>
<td>479±21</td>
</tr>
<tr>
<td>$FRC$ mL</td>
<td>histamine</td>
<td>256±31</td>
<td>312±40</td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM for all subjects (total), subjects with hyperresponsiveness (BHR+) and subjects without hyperresponsiveness (BHR-). $\Delta$: changes relative to control; $VE$: minute ventilation; $fR$: respiratory frequency; $VT$: tidal volume; $FRC$: functional residual capacity. *: $p<0.05$, compared to BHR+; **: $p<0.01$, compared to BHR+; ***: $p<0.05$ compared to control value; ###: $p<0.001$, compared to control value.

**Fig. 2.** - a) Relationship between change in minute ventilation ($\Delta VE$) and change in forced expiratory volume in one second ($\Delta FEV1$) in response to histamine in 44 subjects with hyperresponsiveness (BHR+) and 19 subjects without hyperresponsiveness (BHR-). $\Delta FEV1$ is expressed as percentage change from control values. For BHR+ ($r=0.319, p<0.05$); for BHR- ($r=0.012, p=ns$); for whole group ($r=0.273, p=0.05$). b) Relationship between $\Delta VE$ and histamine concentration in 44 BHR+ and 19 BHR-.

For whole group ($r=0.117, p=ns$). O: BHR+; ▲: BHR-; NS: nonsignificant.
Ventilatory responses to inhalation of histamine determined with the spirometer and by RIP were qualitatively and quantitatively the same, and, as a consequence, the data were pooled. Table 2 presents the results. \( V'E \) increased significantly in BHR- as compared with control values before inhalation of histamine. The changes in \( V'E \) were not significant in BHR+. Breathing frequency increased significantly in the whole group, BHR+ and BHR-. Although, on average, the control values of \( fR \) were higher in BHR+, a further significant increase in \( fR \) was found in response to histamine. In the whole group, BHR+ and BHR-, no significant changes were found in \( Vr \) between control and histamine values. Both control values of \( Vr \) and \( Vt \) after histamine were significantly higher in BHR- as compared to BHR+. Mean±SEM increase in FRC after inhalation of histamine was 0.26±0.03 L, which was 8±1% of predicted. This increase in FRC was significantly (p<0.01) larger in BHR+ than in BHR-.

Figure 2a and b shows the relationships between \( \Delta V'E \) and \( \Delta FEV_1 \) in response to histamine and between \( \Delta V'E \) and the histamine concentration applied, respectively. Results are presented separately for BHR+ and BHR-. A significant correlation was found for the relationship between \( \Delta V'E \) and \( \Delta FEV_1 \) for BHR+ (r=0.319; p<0.05) and for the whole group (r=0.273; p<0.05), but not for BHR-. Thus, it appeared that the subjects with the largest decrease in \( V'E \) showed a relatively large decrease in FEV1. No significant relationship was found between \( \Delta V'E \) and the histamine concentration applied.

**Discussion**

The changes in \( V'E \), \( fR \) and \( Vt \) were not uniform; comparable numbers of subjects responded with increases (n=33) and decreases (n=30) in \( V'E \). For \( fR \), 40 subjects responded with an increase and 23 with a decrease; and for \( Vt \), these numbers were 26 and 37, respectively. These results are in agreement with the observations of Stromberg and Gustafsson [13], who found that 50% of their subjects responded to histamine with an increase in \( V'E \) whereas, in the other 50% \( V'E \) was unchanged or tended to decrease.

The use of a mouthpiece and noseclip may be criticized. Effects of a mouthpiece on breathing pattern have been described in the literature but conclusions are not consistent [3]. In the present study, we have evaluated the effects of inhalation of histamine on respiratory variables. Values after histamine were compared to control values; i.e. before the start of histamine nebulization. Thus, baseline values were obtained after subjects had been connected to the mouthpiece and the nose had been clipped. Hence, the differences in breathing pattern found in response to histamine cannot be attributed to an effect of the mouthpiece or noseclip. It has recently been reported that ventilatory responses (i.e. \( V'E \)) to inhaled histamine, measured by RIP, were diminished when breathing through a mouthpiece whilst wearing a noseclip [13]. All of our subjects breathed through a mouthpiece with the nose clipped. This might explain why we found a considerable number of ventilatory nonresponders. If changes in breathing pattern induced by inhalation of histamine are masked by an effect of the mouthpiece and noseclip, responses in our study may be underestimated.

Histamine may stimulate RARs in two ways: mechanically (by histamine-induced bronchoconstriction) and chemically. In our previous studies in cats [20, 21], we observed that stimulation of RARs either by negative airway pressure or by administration of histamine led to an increase in \( fR \). We think, therefore, that histamine-induced increases in \( fR \) seen in the present study (table 2) were due, at least in part, to a vagal reflex in which RARs are involved.

In the subjects who were BHR+, the response of FRC on histamine was larger than in normal subjects (table 2). This can be attributed to the more pronounced airflow limitation and the possible presence of end-tidal inspiratory activity during increased activity of RARs [20, 21]. An increase in FRC may limit an increase in \( Vt \) or even cause a decrease in \( Vt \) with a concomitant decrease in \( V'E \). Moreover, the increased airway resistance after inhalation of histamine may cause a decrease in \( Vt \) and \( V'E \) in subjects with large decreases in FEV1. This may explain: 1) why we found that \( V'E \) was negatively correlated to \( \Delta FEV_1 \) (fig. 2), i.e. \( V'E \) decreased especially in subjects with large decreases in FEV1 (BHR+); and 2) why the increase in \( V'E \) after histamine was not significant in subjects who were hyperresponsive (table 2). A combination of histamine-induced increases in \( fR \) and bronchoconstriction-induced reductions in \( Vt \) may explain why, in several subjects (n=24), opposite responses were seen, i.e. \( fR \) increased whilst simultaneously \( V'E \) decreased.

We conclude that, in general, respiratory responses to inhaled histamine are not predictable. Respiratory frequency increased significantly both in hyperresponsive and nonhyperresponsive subjects. The concomitant increase in minute ventilation, however, was significant in nonhyperresponsive subjects but not in hyperresponsive subjects. These findings may be interpreted to indicate that different mechanisms with opposite effects may be operating simultaneously, e.g. excitation of central inspiratory activity by stimulation of rapidly-adapting pulmonary stretch receptors, which will promote increases in respiratory frequency, tidal volume and minute ventilation, and bronchoconstriction with increased airway resistance, which will promote decreases in these parameters. As a consequence, depending on the net result of these opposite contributions to, for instance minute ventilation, administration of histamine will cause an increase in minute ventilation in one subject and a decrease in another subject.

**References**

HISTAMINE AND BREATHING PATTERN